Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pervasis Therapeutics

Request full access

Pervasis Therapeutics is a clinical stage company offering a broad portfolio of biologically active therapeutics

Cambridge, United StatesFounded 2003Biotechnology

About Pervasis Therapeutics

Pervasis Therapeutics, founded in 2003, was a clinical-stage biotechnology firm that operated in the regenerative medicine sector. The company was established by a distinguished group including Dr. Elazer Edelman, Dr. Robert Langer, Dr. Joseph Vacanti, and Helen Nugent, based on research partially funded by the Deshpande Center for Innovation at MIT. This founding team, composed of prominent faculty from MIT and Harvard Medical School, leveraged their deep expertise in tissue engineering and vascular biology to address unmet needs in vascular repair.

The company's core business centered on developing biologically active, cell-based therapies to improve the outcomes of common vascular interventions like angioplasties, stents, and bypass grafts. Its primary market consisted of patients suffering from vascular diseases, with a particular focus on those with end-stage renal disease (ESRD) requiring hemodialysis. Pervasis' business model revolved around the research, clinical development, and eventual commercialization of its proprietary technologies, having raised significant venture capital from investors such as Flagship Pioneering, Polaris Partners, and Highland Capital Partners.

Pervasis' flagship product was Vascugel®, a novel, allogeneic cell therapy product. Vascugel® is a cell-based therapeutic gel designed to be placed adjacent to an injured blood vessel during surgical procedures. Its key feature was the use of embedded endothelial cells that provide growth-regulatory compounds to the site of injury. This process was intended to mimic the body's natural healing pathways, promoting vascular health while reducing inflammation, thrombosis, and restenosis (the re-narrowing of the vessel). The product, which had completed Phase II clinical trials, was developed to prevent the failure of arteriovenous grafts and fistulas—critical access sites for hemodialysis patients. In a significant milestone, Pervasis Therapeutics was acquired by Shire plc in April 2012 in a deal potentially valued at up to $200 million, aimed at bolstering Shire's regenerative medicine business.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2003
Headquarters
Cambridge, United States
Open positions
None listed
Sector
Biotechnology
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Aug 2009 $17M $70M Polaris Partners · Flagship Pioneering · Highland Capital Partners —
EARLY VCOther financing Jan 2008 $9.8M $39M Highland Capital Partners · Flagship Pioneering · Polaris Partners —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Pervasis Therapeutics website traffic

Latest recorded traffic for Pervasis Therapeutics is 0 monthly website visits, down 100% over the last three months.

Latest monthly visits0 3-month web change-100%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Pervasis Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Pervasis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A1 investor entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pervasis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pervasis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.